Q1 2024 · 13F-HR
Vivo Capital, LLCholdings as filed
Filed 2024-04-22 · accession 0001213900-24-034979
$1.27B
Reported value
42
Positions
2024-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 834203309 | SLNO | Soleno Therapeutics Inc | $360.3M | 28.3% | 8,418,093 | Common | SOLE |
| 374163103 | GERN | Geron Corp | $89.8M | 7.06% | 27,225,292 | Common | SOLE |
| 413197104 | HRMY | Harmony Biosciences Holdings Inc | $87.5M | 6.88% | 2,606,247 | Common | SOLE |
| P8696W104 | SVA | Sinovac Biotech Ltd. | $76.3M | 6.00% | 11,800,000 | Common | SOLE |
| 05337M104 | — | Avadel Pharmaceuticals PLC | $67.1M | 5.27% | 3,972,099 | Common | SOLE |
| 925050106 | VRNA | Verona Pharma PLC | $58.1M | 4.56% | 3,610,177 | Common | SOLE |
| 00166B105 | ALXO | ALX Oncology Holdings Inc | $47.1M | 3.70% | 4,220,048 | Common | SOLE |
| 26818M108 | DYN | Dyne Therapeutics Inc | $46.4M | 3.65% | 1,635,136 | Common | SOLE |
| 880881107 | 430 | Terns Pharmaceuticals Inc | $43.7M | 3.43% | 6,657,992 | Common | SOLE |
| 04635X102 | CATBUSD | Astria Therapeutics Inc | $32.8M | 2.58% | 2,329,027 | Common | SOLE |
| 92790C104 | VRDN | Viridian Therapeutics Inc | $29.4M | 2.31% | 1,678,207 | Common | SOLE |
| 82686Q101 | SLN | Silence Therapeutics PLC | $23.9M | 1.88% | 1,105,454 | Common | SOLE |
| 68062P106 | OLMA | Olema Pharmaceuticals Inc | $21.2M | 1.67% | 1,873,704 | Common | SOLE |
| 00773U207 | AVU0 | Adverum Biotechnologies, Inc. | $21.2M | 1.67% | 1,500,000 | Common | SOLE |
| 02083G100 | NVLSEUR | Alpine Immune Sciences Inc | $20.8M | 1.63% | 520,505 | Common | SOLE |
| 87650L103 | TARS | Tarsus Pharmaceuticals Inc | $20.6M | 1.62% | 565,550 | Common | SOLE |
| 92337C203 | VSTM | Verastem Inc | $18.2M | 1.43% | 1,538,461 | Common | SOLE |
| 22663K107 | CRNX | Crinetics Pharmaceuticals Inc | $16.4M | 1.29% | 350,000 | Common | SOLE |
| 19240Q201 | COGT | Cogent Biosciences Inc | $15.1M | 1.19% | 2,244,941 | Common | SOLE |
| 81749D107 | SERA | Sera Prognostics Inc | $15.0M | 1.18% | 1,650,440 | Common | SOLE |
| 75915K309 | RGLS | Regulus Therapeutics Inc | $14.4M | 1.13% | 5,000,000 | Common | SOLE |
| 89157D105 | TRML | Tourmaline Bio Inc. | $13.6M | 1.07% | 591,882 | Common | SOLE |
| 20451W101 | CMPS | Compass Pathway PLC | $13.4M | 1.05% | 1,608,000 | Common | SOLE |
| 68622P109 | ORIC | Oric Pharmaceuticals Inc | $11.7M | 0.92% | 849,681 | Common | SOLE |
| 29286M105 | — | Engene Holdings Inc. | $11.5M | 0.90% | 678,705 | Common | SOLE |
| 37186H209 | — | Genetron Holdings Ltd | $10.9M | 0.86% | 2,708,056 | Common | SOLE |
| 449778109 | IOBTQ | IO Biotech Inc | $10.7M | 0.84% | 6,173,439 | Common | SOLE |
| 805111101 | SVRA | Savara Inc | $10.4M | 0.82% | 2,088,323 | Common | SOLE |
| 98887Q104 | ZLAB | Zai Lab Ltd | $8.5M | 0.67% | 531,198 | Common | SOLE |
| 24661P807 | DCTH | Delcath Systems, Inc. | $8.0M | 0.62% | 1,666,746 | Common | SOLE |
| 76200L309 | RZLT | Rezolute Inc | $7.1M | 0.56% | 2,797,704 | Common | SOLE |
| 20454B104 | CMPX | Compass Therapeutics Inc | $7.0M | 0.55% | 3,556,023 | Common | SOLE |
| 45783C200 | TIL | Instil Bio Inc | $6.7M | 0.53% | 624,338 | Common | SOLE |
| 746964105 | QTTB | Q32 Bio Inc. | $6.3M | 0.50% | 370,068 | Common | SOLE |
| 097702104 | BOLT1EUR | Bolt Therapeutics Inc | $4.9M | 0.39% | 3,521,291 | Common | SOLE |
| 90466Y103 | — | Unicycive Therapeutics | $4.8M | 0.38% | 3,470,152 | Common | SOLE |
| 01671P100 | ALLKGUSD | Allakos Inc | $3.8M | 0.30% | 2,988,000 | Common | SOLE |
| 01626L105 | — | Aligos Therapeutics Inc | $3.5M | 0.27% | 3,547,030 | Common | SOLE |
| 23306J101 | — | DBV Technologies SA | $2.0M | 0.16% | 2,708,875 | Common | SOLE |
| 192005106 | CDXS | Codexis, Inc | $1.4M | 0.11% | 388,144 | Common | SOLE |
| 00032Q104 | WHWK | Aadi Bioscience Inc | $1.2M | 0.09% | 509,572 | Common | SOLE |
| 74019P207 | DTIL | Precision Biosciences Inc | $63,395 | 0.00% | 4,675 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.